WallStSmart
HOWL

Werewolf Therapeutics Inc

NASDAQ: HOWL · HEALTHCARE · BIOTECHNOLOGY

$0.63
-8.77% today

Updated 2026-06-05

Market cap
$20.90M
P/E ratio
P/S ratio
10.21x
EPS (TTM)
$-1.21
Dividend yield
52W range
$0 – $2
Volume
0.5M

Werewolf Therapeutics Inc (HOWL) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2019202020212022202320242025
Revenue$0.00$0.00$4.15M$16.40M$19.94M$1.89M$0.00
Revenue growth (YoY)+295.4%+21.6%-90.5%-100.0%
Cost of revenue$463000.00$777000.00$735000.00$2.51M$1.76M$1.81M$1.63M
Gross profit$-463000.00$-777000.00$-735000.00$16.40M$18.18M$71000.00$-1.63M
Gross margin-17.7%100.0%91.2%3.8%
R&D$6.34M$16.64M$35.27M$53.76M$41.78M$56.43M$44.83M
SG&A$3.60M$5.76M$14.82M$18.70M$18.67M$19.05M$15.85M
Operating income$-9.94M$-22.40M$-50.09M$-56.06M$-40.50M$-73.59M$-60.68M
Operating margin-1207.5%-341.8%-203.1%-3904.2%
EBITDA$-9.41M$-14.26M$-49.87M$-54.95M$-32.47M$-64.05M$-59.04M
EBITDA margin-1202.3%-335.1%-162.8%-3397.6%
EBIT$-9.88M$-15.04M$-50.09M$-56.06M$-34.23M$-65.86M$-60.68M
Interest expense$372000.00$101000.00$216000.00$1.10M$3.14M$4.66M$5.27M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-10.99M$-14.94M$-49.77M$-51.56M$-37.37M$-70.52M$-60.82M
Net income growth (YoY)-35.9%-233.1%-3.6%+27.5%-88.7%+13.7%
Profit margin-1199.8%-314.4%-187.4%-3740.8%

Frequently asked questions

How much free cash flow does HOWL generate?

HOWL produced $-60.29M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is HOWL's balance sheet healthy?

HOWL holds $57.95M in cash and equivalents against — in long-term debt, on $24.80M of shareholder equity. That debt is best read against the cash flow the business throws off each year.